Parallel to this federal activity, several pharmaceutical companies began to design and test new chemical compounds. Clinical trials for new AEDs proceeded at a rapid pace during the 1980s. Clinical trials were conducted with progabide, felbamate, gabapentin, lamotrigine, vigabatrin, zonisamide, and topiramate. Several of these have now been approved and brought to the US market. Table 1 shows the time line of AEDs that have been successfully brought to the US market. In addition, there are two AEDs awaiting approval (vigabatrin, zonisamide) and several others in various stages of clinical development (e.g., pregablin, levetiracetam, losigamone, remacemide, oxcarbazepine). As can be seen, since 1993 the pace of introduction of AEDs has been incredibly rapid and the competition fierce. A similar period of rapid advancement occurred from 1946 to 1960 when 13 AEDs were brought to market. However, only 8 of these remain on the US market and only 2 (primidone, ethosuximide) are in widespread use to-day. How many of the AEDs introduced recently will continue to be useful 10 or 20 years from now? How are these new AEDs different from the older AEDs? To attempt to answer any of these questions, it is essential to review the limitations of the current AEDs as well as the limitations of the clinical trials that have been conducted.
What Are the Limitations of Older AEDs?
Older AEDs that have proven useful for the treatment of partial seizures (e.g., phenytoin, phenobarbital, carbamazepine, valproate) have several limitations. Only approximately 20-30% of patients with complex partial seizures become seizure free while taking these drugs. 2 Many of the older agents have similar mechanisms of action: blockade of use-dependent sodium channels. With the exception of valproate, all are potent enzyme inducers of various CYP450 isozymes as well as uridine diphosphate-glucuronyltransferase, and thus have a wide variety of drug interactions. The kinetics of these drugs are also somewhat problematic. Phenytoin, for example, follows nonlinear kinetics and is highly protein bound; carbamazepine undergoes time-dependent auto-induction; and valproate, also a highly protein-bound agent, can be an enzyme inhibitor.
The adverse effects of AEDs are also troublesome, consisting of both concentration-dependent as well as idiosyncratic reactions. In the second Veterans Affairs Cooperative Study, 3 42% of patients treated with either carbamazepine or valproate reported sedation at some time during the 12-month study. Other prominent examples of common adverse effects that both patients and clinicians must deal with include cognitive impairment and blurred or double vision, as well as cosmetic adverse effects such as weight gain and alopecia. In addition, the occurrence of less common adverse effects such as hepatic and/or hematologic toxicities must be considered when using the older AEDs.
Have the new AEDs succeeded in improving drug treatment of epilepsy? To attempt to answer this question, we must look at the clinical trials regarding the indications, efficacy, safety, and pharmacokinetic parameters of these agents.
Limitations of Clinical Trials in Epilepsy
Seizures are the clinical manifestation of abnormal electrical activity in the central nervous system. Epilepsy is defined as the occurrence of two or more unprovoked seizures. Epilepsy is a broad term for a wide variety of syndromes and symptoms. Classification of epilepsy syndromes is becoming much more sophisticated and is assisting clinicians in determining their patients' prognosis as well as designing optimal treatment regimens. The most common type of seizure in adults begins in a discrete area of the brain (partial seizures).
The efficacy rates of the older AEDs depend in large part on the primary outcome measure. Two randomized controlled trials 3,4 conducted in 1100 predominantly male patients with complex partial seizures demonstrated that an "acceptable" balance of seizure control and adverse effects can be achieved with either carbamazepine or phenytoin in approximately two-thirds of the patients, and that these agents were superior to the barbiturates. When freedom from seizures is used as an outcome measure, far fewer patients achieve this goal, unfortunately.
Are the newer drugs any better? Since the goal of treatment is no seizures and no adverse effects, there is a tremendous need for improved seizure control in a large number of patients with epilepsy. Do any of these new drugs get us closer to achieving this goal for the majority of patients? Efficacy results from clinical trials of the newer AEDs report the number of patients who respond to these agents. Response in these trials is generally considered a 50% decrease in seizure frequency. With the newer AEDs, only 20-40% of the patients respond. 5 The number of patients rendered seizure free is usually a very small number (<5%). Why is this? Is this because we used low doses in the clinical trials? Or is it because we used extremely refractory patients? Or could this be due to the fact that the newer drugs really aren't that much better, on average, than the older ones?
Clinical trials in epilepsy are most often conducted in the small percent of patients who continue to have seizures despite optimum treatment with other AEDs. The average patient in these clinical trials has had epilepsy for approximately 20 years and has received at least five AEDs prior to being enrolled in the clinical trial. It is not uncommon to have the "professional" patient, in other words, one who has participated in several of the new AED trials over time. Since these patients have medically refractory epilepsy, it is unethical to discontinue their existing AEDs and then randomize them to receive either the new AED or placebo. Therefore, early clinical trials are almost always done as adjunctive treatment in patients who are receiving other AEDs. Inclusion criteria usually limits the study participants to adults. Young children and the elderly are frequently not studied. In addition, patients with significant concomitant medical or psychiatric conditions are typically excluded from initial efficacy evaluations. Since partial seizures are most common, most initial trials exclude patients with primary generalized epilepsies. These are the clinical criteria for study entry; therefore, the official FDA indications for most of the newer drugs is "adjunctive therapy of partial seizures in adults." It is usually only during postmarketing studies that other age groups, other seizure types, and new-onset seizures are explored. Unfortunately, this apparent uniformity on drug introduction gives the impression that these agents are identical, and therefore, presumably interchangeable. This is probably not true. As an example, lamotrigine was initially indicated only for adjunctive treatment of partial seizures in adults. Subsequent clinical trials have proven efficacy as monotherapy in adults and in patients aged 2-12 years as adjunctive treatment of generalized seizures associated with Lennox-Gastaut syndrome. 6 Postmarketing trials and clinical experience no doubt provide us with the most useful information as to the clinical utility of these new AEDs.
Another vexing question for clinicians is, What about initial therapy? Can clinicians long accustomed to using the older AEDs such as phenytoin and carbamazepine as initial therapy reasonably extrapolate data from "add-on" studies in patients with refractory seizures as proof of efficacy in other situations, such as the newly diagnosed patients, or as monotherapy? The answer is probably no. FDA requirements for approval as adjunctive therapy state that an AED must demonstrate both efficacy and safety, and that these outcomes can be differentiated from a placebo effect. By definition, these trials are complicated both in terms of efficacy and adverse effects by pharmacokinetic and pharmacodynamic interactions. Registration as monotherapy, however, presents numerous other challenges. Clearly, given the nature of the condition studied (medically refractory epilepsy), randomizing these patients to receive a placebo would not be ethical.
Demonstration of therapeutic equivalence of a newer AED to an older, established AED is not acceptable to the FDA. In such trial designs, although therapeutic equivalence of a study drug to an older AED may be interpreted as proof of efficacy, an alternative explanation could conceivably be that both the study drug and older comparator AED are equally ineffective. Consequently, "therapeutic failure" designs, in which the study drug must demonstrate statistical superiority to a less than therapeutic dose of another AED, are preferred. While these designs may demonstrate efficacy, they still do not help us answer the equally clinically relevant question of which AED is better. 7 Unfortunately, we do not have a comparative study of the newer AEDs against each other. Meta-analysis of the newer AEDs, 5 using data from previously published clini-cal trials, does provide some limited insight. In this analysis, there were no statistically significant differences in either efficacy or adverse effects between the AEDs reviewed (lamotrigine, gabapentin, topiramate, vigabatrin). While clinical differences in response rates were not tremendously different, one must recognize that for gabapentin and lamotrigine, as with many other drugs, the doses used in clinical trials were generally lower than those used in current practice. Conversely, topiramate and vigabatrin were studied at doses now considered to be at the higher end of the dosing spectrum. In any event, all the newer AEDs appear effective in the treatment of partial seizures. Troublesome adverse effects such as sedation usually occur less frequently with the newer agents, especially lamotrigine, gabapentin, and vigabatrin. Will we ever conduct a true comparative study between the newer AEDs? Unfortunately, this is probably unlikely to be done in the near future due to the high cost of conducting such studies and the question of which AEDs should be compared.
Are the New Drugs Safe?
Most of the newer agents have been tested in approximately 2000-3000 patients when the new drug application was submitted. Though the common adverse effects in patients taking other AEDs can be identified during the clinical trials, the rare adverse effects will be missed. In addition, these studies are conducted in refractory patients who have received several other AEDs in the past; thus, these patients are accustomed to AED adverse effects and may not report these problems as readily as would the AEDnaïve patient.
Standardized adverse effect assessments are not used in these trials; only adverse effects spontaneously or unsystematically reported by patients are documented. Therefore, the initial postmarketing adverse effect profile of a new AED may not truly reflect the incidence or magnitude of adverse effects seen after more widespread clinical use. An example of this is felbamate. During clinical trials felbamate was considered to be extremely safe. Animal toxicity models indicated a wide protective index (difference between lethal dose and effective dose). During the clinical trials patients appeared to tolerate the drug very well. However, during the first year of felbamate's clinical use the dose-initiation adverse effects of insomnia and headache became very apparent. In addition, 1 year and approximately 100 000 patients after felbamate's introduction, an increased incidence of aplastic anemia and liver dysfunction was detected. This setback has made the neurology community very cautious in using any of the newer drugs until 100 000 patients have been treated. To date, serious hematologic, hepatic, or biochemical adverse effects have not been uncovered for any of the other newer AEDs.
Where Do the New AEDs Fit?
As of October 1998, the newer AEDs have gained only a small portion of the AED market. Phenytoin continues to be the leader in the number of prescriptions written, with carbamazepine and valproate close behind. Gabapentin is Editorial gaining in numbers; however, much of its use is attributed to indications other than epilepsy. Lamotrigine, topiramate, and tiagabine each have less than 5% of the AED market. Why is the adoption of these new AEDs so slow? Why aren't we using them sooner? Is it because the newer AEDs are not really any different or better than the older ones? Is this apparent lack of increased efficacy true or just perception? Today, the newer AEDs are being used primarily in patients who have failed at least one traditional AED. In fact, patients have often failed the three major AEDs (phenytoin, carbamazepine, valproate) before we consider using a newer agent. Once patients have failed more than one AED, the likelihood of response to other agents decreases significantly. 8 Thus, we are using the new AEDs in patients whose seizures are the most difficult to control. Is it any wonder that several of the recently approved AEDs have gotten the reputation of not being very good? Should we be using these newer AEDs in patients with new-onset epilepsy? Perhaps. So, why aren't we?
Part of the answer to this is conservatism. The old AEDs are our friends. We know what to expect from them. The newer AEDs are still unknowns, and we remain somewhat cautious because of their newness. However, both gabapentin and lamotrigine have now had greater than one million patient exposures, and topiramate has been used in more than 100 000 patients. Fear of the unusual adverse effect can't be the only explanation for lack of use.
Are these new drugs harder to use? Not really; the newer AEDs have much simpler pharmacokinetics than the older AEDs. All appear to be linear and only tiagabine is significantly protein bound. All have a far lower propensity to cause pharmacokinetic interactions, although several are subject to enzyme induction (lamotrigine, tiagabine, topiramate). Gabapentin and vigabatrin are not metabolized and are renally excreted. These agents are unique in that they are not subject to kinetic interactions. Topiramate and felbamate are eliminated both through metabolism and renal excretion. With the exception of gabapentin, absorption of the newer AEDs appears to be rapid and complete. There are clear dose-response relationships, but therapeutic ranges have yet to be fully defined and serum concentration monitoring is probably less necessary than with the older AEDs. The only difficulty with dosing these AEDs is the slow dosage titration several of them require. This, however, is due to patient tolerability rather than pharmacokinetic concerns. So, it is probably not the pharmacokinetics that are preventing more widespread use.
In addition to kinetic differences, the newer AEDs have, in many cases, novel and different mechanisms of action. More emphasis has been placed on inhibitory and excitatory neurotransmission. Several γ-aminobutyric acid (GABA)ergic drugs are approved (tiagabine, gabapentin) or are awaiting approval (vigabatrin). Drugs that inhibit or block excitatory neurotransmission are rapidly approaching approval. Do these newer mechanisms provide improvements in the care of the patient with epilepsy? Will knowledge of an AED's mechanism of action help tailor and individualize therapy? For example, clinical experience suggests that GABAergic drugs may not possess significant efficacy in the treatment of primary generalized epilepsy and may, in fact, exacerbate some seizures. 9
Can we use combinations of AEDs to improve efficacy? For example, would a combination of a drug that blocks N-methyl-D-aspartic acid receptors yet increases GABA neurotransmission result in improved seizure control? This is the premise of rational polypharmacy, a concept theorizing that combining AEDs with differing mechanisms of actions may yield improved efficacy. 10 Would this improved seizure control be counterbalanced by an increased risk of adverse effects? Studies to answer these questions have yet to be done.
What About Cost?
The newer AEDs are more expensive to acquire than the older AEDs ( Table 2) . 11 However, other costs such as serum concentration and laboratory monitoring, and possi-1242 s The Annals of Pharmacotherapy s 1998 November, Volume 32 
What of the Future?
Will companies continue to support these newer drugs despite less-than-impressive sales? This, in part, may depend on the clinical usefulness of these drugs in disease states other than epilepsy. More than half of carbamazepine's and valproate's sales are for disorders other than seizures. Some of the newer AEDs are also being used for other indications. Gabapentin is widely used for neuropathic pain. Lamotrigine and gabapentin are being actively evaluated for the treatment of mood disorders. Given its mechanism of action (inhibition of synaptic GABA reuptake), tiagabine may be useful in spasticity. Who will do the research to prove safety and efficacy in these disorders? Patent life may limit the sponsoring company from conducting other studies. Should these studies in other disorders be done during the initial clinical trials? How can we predict which drugs will be useful for other disorders?
The key to future development may lie in the answers to these fundamental questions.
What Should Clinicians Do Today?
Given all the potential advantages of these newer agents, we are then left with the still nagging question: Should clinicians be using the newer AEDs more readily? The answer is not clear; however, from a clinician's point of view, the individual patient must be considered. All the above factors should be considered, as well as the fact that none of these drugs is dramatically different from the older AEDs. Though the newer AEDs are only incrementally better when viewed at the population level (e.g., clinical trials), for an individual patient, any one of these newer AEDs could be the "magic bullet" that renders the individual seizure free. At this time, it is relatively impossible to predict which patients will respond to what AED. Thus, the answer to our initial question, Do we need these new drugs?, is yes. All the AEDs should be made available, and should be tried in patients who are either not responding to their current therapy or are experiencing troubling adverse effects. How many AEDs should we try? That depends on the patience of the patient and their desire to be seizure free. Healthcare practitioners should not decide this for the patients. We owe it to them to continue to offer new AEDs and to be honest about the possible benefits and risks.
